Delays in closing larger integrated service contract(s) currently under discussion and continued weakness in its traditional smaller contract base have caused Fusion to issue a trading statement warning that its FY23 revenues are likely to be materially below market expectations. This has had a predictable impact on the share price, down c. 25% yesterday, despite there being a good chance that a large contract will still be awarded in the near term, albeit with revenue falling into FY24. We have ....
07 Mar 2023
Fusion Antibodies Update
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fusion Antibodies Update
Fusion Antibodies Plc (FAB:LON) | 3.2 0 (-9.2%) | Mkt Cap: 3.08m
- Published:
07 Mar 2023 -
Author:
Robin Davison | John Savin -
Pages:
5
Delays in closing larger integrated service contract(s) currently under discussion and continued weakness in its traditional smaller contract base have caused Fusion to issue a trading statement warning that its FY23 revenues are likely to be materially below market expectations. This has had a predictable impact on the share price, down c. 25% yesterday, despite there being a good chance that a large contract will still be awarded in the near term, albeit with revenue falling into FY24. We have ....